The incorporation of novel targeted therapies to radiation therapy is of particular interest
in head and neck cancer and may improve efficacy without significantly increasing toxicity.
The investigators hypothesize that the addition of a second EGFR-targeted agent that inhibits
EGFR at the intracellular level will improve the antitumor effect of standard radiation and
cetuximab. The goal of this study is to evaluate the safety, efficacy, and the biologic
effects in patients with locally advanced SCCHN of an antisense gene targeting the EGFR in
combination with standard therapy with radiation and cetuximab.